The Food and Drug Administration has approved a topical anticholinergic, sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis in adults and children aged ≥ 9 years.

NASHVILLE, Tenn., March 9, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development of non-invasive treatments for hyperhidrosis or ...

Hyperhidrosis most commonly affects the armpits, followed by the palms of the hands and the soles of the feet. Impairment of quality of life differs based on where primary hyperhidrosis manifests on ...

Sofpironium bromide in the treatment of primary axillary hyperhidrosis improves Hyperhidrosis Disease Severity Scale scores, reduces gravimetric weight of sweat, and improves Dermatology Life Quality ...

Dongwha Pharm announced on July 6 that ECCLOCK Gel, the first prescription medication for primary axillary hyperhidrosis ...

Please provide your email address to receive an email when new articles are posted on . Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, ...

Young adults with excessive sweating, or axillary hyperhidrosis, experience high levels of social difficulties and anxiety. Microwave thermolysis reduces sweating and is associated with reduced social ...

Please provide your email address to receive an email when new articles are posted on . Sofdra (sofpironium) gel 12.45% is the first and only chemical entity for primary axillary hyperhidrosis. The ...

Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...

MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering ...